DMAC Stock — DiaMedica Therapeutics Inc.: Cash, EV, Pipeline

Share price

$6.85

Market cap

$369.4M

Cash

$43.5M

Enterprise value

$325.9M

Balance sheet

Cash	$43.5M
Debt	$0.0M
Net cash	$43.5M
Enterprise value	$325.9M
Basic shares	53.9M shares
Fully diluted shares	65.8M shares
Fully diluted market cap	$450.8M
Cash per share	$0.81

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading DMAC daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23	Recombinant human tissue kallikrein	Phase 3	Acute Stroke; Ischemic Stroke; Stroke	Q1 2027

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

DM199

Phase 2/3 · Active Modality: recombinant protein (enzyme)

Aliases rinvecalinase alfa, rhKLK1

Target KLK1 (tissue kallikrein-1)

Indications

acute ischemic stroke (AIS) (Phase 2/3)
preeclampsia (PE) (Phase 2)
fetal growth restriction (FGR) (Phase 2)

Catalysts

— September/October 2026
— end of 2026

Status note Lead product candidate; first pharmaceutically active recombinant form of human tissue kallikrein-1 (KLK1), a serine protease enzyme. AIS: Phase 2/3 adaptive ReMEDy2 trial ongoing (site activation/enrollment slower than expected). PE: Phase 2 investigator-sponsored proof-of-concept trial at Tygerberg Hospital, Cape Town; Part 1a completed June 2026 (sustained reductions in maternal blood pressure reported). FGR: Part 3 of same IST. Prior clinical hold lifted June 2023.

Per-asset detail extracted from the 10-Q filed 2026-08-10. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Recombinant human tissue kallikrein
Lead indication	Acute Stroke
Lead phase	Phase 3
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05065216	Phase 3	Recruiting	Sponsor	DMAC	—	Acute Stroke; Ischemic Stroke; Stroke	Q1 2027

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for DiaMedica Therapeutics Inc on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

DMAC — DiaMedica Therapeutics Inc.